277 related articles for article (PubMed ID: 6092607)
1. Role of spinal mu opioid receptors in the development of morphine tolerance and dependence.
DeLander GE; Portoghese PS; Takemori AE
J Pharmacol Exp Ther; 1984 Oct; 231(1):91-6. PubMed ID: 6092607
[TBL] [Abstract][Full Text] [Related]
2. Spinal antagonism of tolerance and dependence induced by systemically administered morphine.
Delander GE; Takemori AE
Eur J Pharmacol; 1983 Oct; 94(1-2):35-42. PubMed ID: 6686142
[TBL] [Abstract][Full Text] [Related]
3. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal beta-funaltrexamine antagonizes intracerebroventricular beta-endorphin- but not morphine-induced analgesia in mice.
Suh HH; Tseng LF
J Pharmacol Exp Ther; 1988 May; 245(2):587-93. PubMed ID: 2966856
[TBL] [Abstract][Full Text] [Related]
5. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo.
Yoburn BC; Gomes BA; Rajashekara V; Patel C; Patel M
Synapse; 2003 Feb; 47(2):109-16. PubMed ID: 12454948
[TBL] [Abstract][Full Text] [Related]
6. Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine.
Adams JU; Paronis CA; Holtzman SG
J Pharmacol Exp Ther; 1990 Dec; 255(3):1027-32. PubMed ID: 2175793
[TBL] [Abstract][Full Text] [Related]
7. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
8. Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism.
Jiang Q; Seyed-Mozaffari A; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1995 May; 273(2):680-8. PubMed ID: 7752070
[TBL] [Abstract][Full Text] [Related]
9. Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in beta-funaltrexamine-treated mice.
Takemori AE; Portoghese PS
J Pharmacol Exp Ther; 1987 Oct; 243(1):91-4. PubMed ID: 2822908
[TBL] [Abstract][Full Text] [Related]
10. Cellular mechanisms of opioid tolerance: studies in single brain neurons.
Christie MJ; Williams JT; North RA
Mol Pharmacol; 1987 Nov; 32(5):633-8. PubMed ID: 2824980
[TBL] [Abstract][Full Text] [Related]
11. Effects of chronic morphine administration on the mu and delta opioid responses in the CA1 region of the rat hippocampus.
Wimpey TL; Opheim KE; Chavkin C
J Pharmacol Exp Ther; 1989 Nov; 251(2):405-11. PubMed ID: 2553917
[TBL] [Abstract][Full Text] [Related]
12. mu-Opioid receptor internalization-dependent and -independent mechanisms of the development of tolerance to mu-opioid receptor agonists: Comparison between etorphine and morphine.
Narita M; Suzuki M; Narita M; Niikura K; Nakamura A; Miyatake M; Yajima Y; Suzuki T
Neuroscience; 2006; 138(2):609-19. PubMed ID: 16417975
[TBL] [Abstract][Full Text] [Related]
13. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
14. Modification of mu-opioid agonist-induced locomotor activity and development of morphine dependence by diabetes.
Kamei J; Ohsawa M; Saitoh A; Iwamoto Y; Suzuki T; Misawa M; Nagase H; Kasuya Y
J Pharmacol Exp Ther; 1995 Aug; 274(2):700-6. PubMed ID: 7636731
[TBL] [Abstract][Full Text] [Related]
15. Glycyl-glutamine, an endogenous beta-endorphin-derived peptide, inhibits morphine-induced conditioned place preference, tolerance, dependence, and withdrawal.
Cavun S; Göktalay G; Millington WR
J Pharmacol Exp Ther; 2005 Nov; 315(2):949-58. PubMed ID: 16079299
[TBL] [Abstract][Full Text] [Related]
16. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
Wang HY; Friedman E; Olmstead MC; Burns LH
Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
[TBL] [Abstract][Full Text] [Related]
17. Blocking mu opioid receptors in the spinal cord prevents the analgesic action by subsequent systemic opioids.
Chen SR; Pan HL
Brain Res; 2006 Apr; 1081(1):119-25. PubMed ID: 16499888
[TBL] [Abstract][Full Text] [Related]
18. Tolerance to intrathecal oxymetazoline-induced analgesia, with paradigm-dependent cross-tolerance to intrathecal morphine.
Sherman SE; Loomis CW; Milne B; Cervenko FW
J Pharmacol Exp Ther; 1988 Apr; 245(1):319-26. PubMed ID: 3361450
[TBL] [Abstract][Full Text] [Related]
19. Relative involvement of supraspinal and spinal mu opioid receptors in morphine dependence in mice.
Miyamoto Y; Takemori AE
Life Sci; 1993; 52(12):1039-44. PubMed ID: 8383266
[TBL] [Abstract][Full Text] [Related]
20. Resting and evoked spinal substance P release during chronic intrathecal morphine infusion: parallels with tolerance and dependence.
Gu G; Kondo I; Hua XY; Yaksh TL
J Pharmacol Exp Ther; 2005 Sep; 314(3):1362-9. PubMed ID: 15908510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
